Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 10/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561022 | 0.86 | HTR1D (0.55) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL13063071 | 0.86 | LMNA (0.64) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL560405 | 0.85 | LMNA (0.71) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL8146712 | 0.83 | SMN1; SMN2 (0.53) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL8148008 | 0.83 | LMNA (0.52) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL561403 | 0.83 | LMNA (0.62) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL560664 | 0.80 | LMNA (0.56) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL560745 | 0.78 | LMNA (0.55) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL8139996 | 0.78 | HTR1D (0.52) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL17188805 | 0.78 | LMNA (0.55) | LMNAGAAAPOBEC3ACTDSP1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035235-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | LMNA 1467/4885GAA 751/4885APOBEC3A 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.